靶向TGR5-GLP-1通路以对抗2型糖尿病和非酒精性脂肪性肝病。

Targeting the TGR5-GLP-1 pathway to combat type 2 diabetes and non-alcoholic fatty liver disease.

作者信息

Pols T W H, Auwerx J, Schoonjans K

机构信息

Laboratory of Integrative and Systems Physiology (LISP), Ecole Polytechnique Fédérale de Lausanne, 1015 Lausanne, Switzerland.

出版信息

Gastroenterol Clin Biol. 2010 Apr-May;34(4-5):270-3. doi: 10.1016/j.gcb.2010.03.009. Epub 2010 May 4.

DOI:10.1016/j.gcb.2010.03.009

PMID:20444564

Abstract

Incretin-based therapies have shown promise in the treatment of type 2 diabetes. Here we review our current understanding of TGR5 as a target to induce glucagon-like peptide-1 (GLP-1) secretion. These new observations suggest that TGR5 agonists may constitute a novel approach to treat type 2 diabetes, as well as complications of diabetes, such as non-alcoholic fatty liver disease.

摘要

基于肠促胰岛素的疗法在2型糖尿病治疗中已显示出前景。在此，我们综述了目前对TGR5作为诱导胰高血糖素样肽-1（GLP-1）分泌靶点的认识。这些新发现表明，TGR5激动剂可能构成一种治疗2型糖尿病以及糖尿病并发症（如非酒精性脂肪性肝病）的新方法。